Rotigotine: High-Affinity Dopamine D2/D3 Agonist for Parkinson’s Disease Research

Executive Summary: Rotigotine is a synthetic dopamine receptor agonist with high affinity for D2 and D3 subtypes, supporting its use in Parkinson’s disease research (Ouchi et al., 2022). The compound exhibits a Ki of 13 nM for D2 and 0.71 nM for D3 receptors, and binds to 5-HT1A and adrenergic α2B receptors. Bench studies confirm antiparkinsonian activity in rodent models. Rotigotine is supplied by APExBIO (SKU A3776) at ≥98% purity and is compatible with cell-based and in vivo workflows. It is most stable when stored at -20°C and is insoluble in water but readily soluble in DMSO and ethanol at specified concentrations (APExBIO product page).

Biological Rationale

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (Ouchi et al., 2022). Dopamine receptor agonists, such as Rotigotine, target the underlying dopaminergic deficit. Dopaminergic signaling modulates both motor and non-motor symptoms, including lower urinary tract dysfunction and cognitive impairment. Rotigotine’s receptor profile enables research into both canonical motor pathways and broader neurophysiological processes affected in PD. Its cross-reactivity with 5-HT1A and α2B adrenoceptors allows exploration of serotonergic and adrenergic interactions in the PD context. APExBIO’s Rotigotine is used to model PD-related phenotypes in vitro and in vivo, facilitating translational research (APExBIO).

Mechanism of Action of Rotigotine

Rotigotine acts as an agonist at dopamine D2 and D3 receptors, with additional affinity for D1, D4, D5, 5-HT1A, and α2B adrenergic receptors (Ouchi et al., 2022). At the molecular level, it mimics dopamine by binding to postsynaptic and presynaptic dopamine receptors. This interaction stimulates adenylyl cyclase inhibition via Gi/o-coupled D2-like receptors, reducing cAMP levels and modulating neuronal excitability. Rotigotine’s activity at D3 receptors is particularly relevant for non-motor symptoms and motivational processes. Its secondary binding to 5-HT1A and α2B adrenoceptors may influence serotonergic and noradrenergic tone, with implications for autonomic and mood regulation. The compound’s pharmacokinetics allow for sustained receptor engagement in preclinical models, especially when delivered transdermally or by injection. Transdermal delivery offers stable plasma concentrations for up to 24 hours in animal studies (Ouchi et al., 2022).

Evidence & Benchmarks

• Rotigotine exhibits high binding affinity for D2 (Ki = 13 nM) and D3 (Ki = 0.71 nM) receptors, supporting its role as a potent dopaminergic agonist (APExBIO).
• Single-dose intravenous administration (0.25 or 0.5 mg/kg) in 6-OHDA-lesioned rat PD models significantly reduced intercontraction interval (ICI) and voiding pressure (VP) compared to vehicle controls (p < 0.05) (Ouchi et al., 2022).
• Subcutaneous dosing increased ICI at 2 hours post-administration, indicating modulation of lower urinary tract function (Ouchi et al., 2022).
• Rotigotine is insoluble in water but soluble at ≥58 mg/mL in DMSO and ≥25.25 mg/mL in ethanol, enabling flexible assay design (APExBIO).
• Transdermal delivery achieves stable plasma concentrations, supporting reproducible behavioral and biochemical outcomes (Ouchi et al., 2022).
• APExBIO supplies Rotigotine at ≥98% purity for scientific use, ensuring batch-to-batch reproducibility (APExBIO).

This article expands upon prior application notes (Rotigotine (SKU A3776): Bench-Validated Dopamine D2/D3 Ag...) by providing mechanistic and benchmarking data directly derived from peer-reviewed studies.

For a broader translational outlook, see Rotigotine as a Next-Generation Dopaminergic Modulator: M..., which focuses on clinical pipeline integration. This article centers on preclinical evidence and quantitative performance metrics.

The solubility and workflow recommendations here extend product-centric reviews such as Rotigotine: Dopamine Receptor Agonist for Parkinson’s Dis... by detailing experimental constraints and assay compatibility.

Applications, Limits & Misconceptions

Rotigotine’s robust receptor profile enables its use in:

• Modeling dopaminergic signaling in cell-based and animal assays.
• Preclinical studies of motor and non-motor symptoms in Parkinson’s disease.
• Interrogating serotonergic and adrenergic pathways via secondary receptor interactions.
• Testing delivery systems, including transdermal and subcutaneous approaches.

Common Pitfalls or Misconceptions

• Rotigotine is not a selective D2/D3 agonist; it also binds D1, D4, D5, 5-HT1A, and α2B adrenoceptors.
• The compound is insoluble in water; improper dissolution can compromise assay validity (APExBIO).
• Solutions are unstable long-term and should be prepared fresh for each experiment.
• For research use only; not intended for diagnostic or therapeutic clinical applications.
• Translational relevance to human PD symptoms should be interpreted cautiously, as rodent models do not fully recapitulate the human disease spectrum (Ouchi et al., 2022).

Workflow Integration & Parameters

Rotigotine’s physical and chemical properties support diverse experimental designs. It is provided as a crystalline solid, with a molecular weight of 315.47 and molecular formula C19H25NOS. Dissolve at ≥58 mg/mL in DMSO or ≥25.25 mg/mL in ethanol for use in cell-based assays. Store at -20°C for optimal stability. Prepare fresh solutions; avoid extended storage post-dilution. For in vivo studies, validated dosing ranges from 0.125–0.5 mg/kg in rats, administered intravenously or subcutaneously (Ouchi et al., 2022). Transdermal delivery can achieve stable plasma levels over 24 hours. Monitor temperature and light exposure to maintain compound integrity. For dose-response or cytotoxicity assays, consult batch-specific purity data and adjust concentrations accordingly. Refer to the Rotigotine product page for handling and compatibility details.

Conclusion & Outlook

Rotigotine, as provided by APExBIO (SKU A3776), is a benchmark dopamine D2/D3 receptor agonist for Parkinson’s disease research. Its well-characterized affinity profile, solubility, and stability parameters make it indispensable for reproducible studies of dopaminergic signaling. While not exclusively selective, its activity across multiple receptor systems broadens its application in neuroscience. Future research will benefit from integrating Rotigotine into advanced delivery systems and combinatorial models. For further guidance on cell-based implementation, see Rotigotine (SKU A3776): Bench-Validated Dopamine D2/D3 Ag....